Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

@inproceedings{Helm2013AzacitidineMB,
  title={Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients},
  author={Lieke H van der Helm and Ellen RM Scheepers and Nic Jgm Veeger and Simon M. G. J. Daenen and Andr{\'e} B. Mulder and Eva van den Berg and Edo Vellenga and Gerwin A. Huls},
  booktitle={Journal of hematology & oncology},
  year={2013}
}
BACKGROUND Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating agents in older AML patients in unselected patient populations. METHODS To compare the effectiveness of azacitidine with conventional therapy, we collected data of 227 consecutive AML patients (≥60 years) who were treated with azacitidine (N = 26), intensive chemotherapy (N… CONTINUE READING